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Abstract A 70 year-old female patient presented with
fever, nausea and dyspnea. She had been receiving
immunosuppressive therapy with methotrexate and pred-
nisone for large-vessel vasculitis. The patient was shown to
have coexistent Pneumocystis jiroveci pneumonia and
primary cytomegalovirus (CMV) infection with presumed
CMV pneumonitis and colitis. To our knowledge, this is
the first case report on the occurrence of combined primary
cytomegalovirus and Pneumocystis jiroveci infection in a
patient with vasculitis. It illustrates the importance of being
aware of the possibility of combined opportunistic infec-
tions in patients with rheumatologic diseases.
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Introduction
Opportunistic infections frequently occur in immunocom-
promised patients such as HIV-infected patients, transplant
recipients receiving immunosuppressive therapy and
patients with neoplasm or rheumatologic diseases. In
patients with rheumatologic diseases, opportunistic infec-
tions can largely be attributed to steroid use and low
lymphocyte counts [1–3]. Complications due to these
infections are most frequent in patients with systemic lupus
erythematosus (SLE) and to a lesser extent in rheumatoid
arthritis (RA) [4]. They also present a major risk to patients
with systemic vasculitis [5].
Cytomegalovirus (CMV) is a DNA virus belonging to
the herpes viridae family. It remains latent within the body
after the initial infection and can be reactivated when the
immune system is impaired. Between about 40 and 90% of
the population in central Europe and the US carry cyto-
megalovirus [6, 7]. CMV disease is frequently reported in
immunocompromised patients [8]. Common symptoms are
nausea, fever, sweating and abnormal liver function [9].
CMV diseases reported in the literature are usually due to
reactivation of CMV in immunocompromised patients and
transplant recipients [10, 11]. Over 90% of elderly persons
have antibodies against CMV indicating previous primary
infection [6]. Thus, primary CMV infection rarely occurs
in the elderly.
CMV disease may be accompanied by co-infections.
This may partly be due to its immunosuppressive effect
[12]. Combined cytomegalovirus and Pneumocystis jiro-
veci infection has been described in the literature and
may be fatal [13]. It generally affects young patients
with HIV-AIDS and reactivation of the cytomegalovirus
[14].
Here we present a 70 year-old patient with the unique
combination of primary cytomegalovirus infection, Pneu-
mocystis jiroveci pneumonia and vasculitis. The unusual
occurrence of primary cytomegalovirus infection in this
age group emphasizes the importance of close monitoring
of immunosuppressed patients in all age groups. Elderly
immunosuppressed patients have a greater likelihood of
contracting more than one opportunistic infection, thereby
increasing the risk of a fatal outcome.
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Case report
The 70 year-old female patient was admitted to our hos-
pital with elevated body temperature (up to 38.3C) and
progressive nausea. She had been receiving oral steroids
(prednisone 30 mg/day) and methotrexate once a week for
5 weeks for unclassified ANCA-negative large-vessel
vasculitis, which had been diagnosed 1 year earlier. The
patient had a history of arterial hypertension, glaucoma,
chronic bronchiectasia with lobe resection of the left lung
in 1977, partial thyroidectomy due to nodule in 1997,
breast cancer with surgery, chemotherapy and radiation in
1997, tuberculosis in 1947 and partial bowel resection due
to diverticulitis.
On admission, the patient complained of fatigue, nausea,
vomiting, listlessness and mild dyspnea. These symptoms
had started 3 weeks earlier, directly after a methotrexate
injection. In the week preceding admission, she had
developed temperatures of up to 38.3C, usually in the
morning. Two days before admission, the nausea had
increased and she had started to throw up.
No focus of infection could be found in the physical
examination. Urine and blood cultures were negative.
Pathologic laboratory findings are summarized Table 1. CT
scan of chest and abdomen showed no signs of inflam-
mation. Chest X-ray showed also no interstitial pneumo-
nitis. Serologic tests and bronchoalveolar lavage (BAL)
were performed. Serology showed the pattern of primary
cytomegalovirus infection with positive CMV IgG anti-
bodies and IgM antibodies of intermediate avidity. Active
cytomegalovirus infection was confirmed by positive
antigenemia with a viral load of two million copies (PCR).
A retrospective analysis of frozen serum samples taken
1 year earlier was negative for IgG and IgM anti-CMV
antibodies.
Cytomegalovirus was also isolated from BAL fluid with
5.18 million copies in the PCR. Bronchoscopy of the left
inferior lobe demonstrates a severe inflammation of the
bronchial system (Fig. 1). BAL fluid also showed an
unexpected positive cytology for Pneumocystis jiroveci
(immunofluorescence in situ hybridization).
Methotrexate was discontinued and steroids were
reduced to 20 mg prednisone per day. Treatment was ini-
tiated with intravenous pentamidine (due to known tri-
methoprim/sulfamethoxazole allergy) for 8 days and
ganciclovir for 10 days. This therapy resulted in complete
recovery within 10 days and the patient was discharged
17 days after admission. Drug prophylaxis was initiated for
CMV and PCP infection. Follow-up visits were uneventful
1 year after discharge.
Discussion
Our case report demonstrates the unique occurrence of
combined Pneumocystis jiroveci pneumonia and primary
cytomegalovirus infection in an elderly patient with large-
vessel vasculitis.
Symptomatic CMV infections in immunocompetent
patients usually occur in younger age groups and are rare in
the elderly [15]. The diagnosis of primary CMV infection
in this 70 year-old patient was based on serologic findings
showing seroconversion and a high titer of CMV IgM
antibodies of intermediate avidity. The patient also had
positive antigenemia and a high viral load as determined by
PCR. It is most likely that the patient’s gastrointestinal
Table 1 Pathological findings in the laboratory
Pathologic laboratory findings On admission On discharge Maximal values Normal values
C-reactive protein (mg/l) 31.0 8.9 60.8 0–10.0
White blood cell count (G/l) 2.41 14.1 17.0 3.5–10.0
Lymphocytes (G/l) 3.36 4.59 5.25 0.9–3.3
CD4? counts (cells/mcl) – – 1198 700–1100
ASAT (U/l) 42 59 336 11–36
ALAT (U/l) 63 126 454 10–37
GGT (U/l) 75 361 519 8–49
Bilirubin mcmol/l 12 11 13 5–18
CMV-IgG (S/CO) 2.5 – – \0.90
CMV-IgG Avidity (Index) 0.201 – – \0.30
CMV-IgM (S/CO) 5.4 – – \0.90
CMV PCR (copies/ml) in BAL 5.18 9 106 – – ND
CMV PCR (copies/ml) in blood 2.00 9 106 – – ND
BAL bronchoalveolar lavage fluid
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symptoms were caused by the primary CMV infection, but
no colonoscopy was performed to confirm CMV colitis.
CMV was also isolated from BAL fluid suggesting CMV
pneumonia. However, a positive BAL finding for CMV is
common in patients with multiple opportunistic pulmonary
infections, including Pneumocystis jiroveci infection, and
cannot generally be equated to CMV pneumonia [15]. A
study of asymptomatic HIV-infected subjects showed that
BAL cultures were positive for CMV in nine out of 19
subjects irrespective of their pulmonary symptoms [16].
CMV infection coexisting with PCP is of clinical rele-
vance, however. In a Danish study it could be shown that
the mortality of patients receiving steroids for Pneumo-
cystis jiroveci infection doubled when there was concom-
itant CMV infection [17]. Niolles et al. [18] suggested that
CMV infection was responsible for fatal outcomes in
patients developing opportunistic fungal and bacterial
infections after hematopoietic stem cell transplantation.
The unique feature in our case was the occurrence of
combined primary CMV infection and Pneumocystis jiro-
veci pneumonia in an elderly patient with vasculitis.
Rheumatologic diseases including vasculitis themselves
can cause immunosuppression. In addition, the patient
received an immunosuppressive regimen of steroids and
methotrexate. Steroid treatment has been shown to be a risk
factor for opportunistic infections in patients with rheu-
matologic diseases [1–3, 19]. While immunosuppressive
therapy is important for controlling the underlying disease,
it should not be initiated without considering the risk of
infection. In order to prevent cytomegalovirus and pneu-
mocystis infection, chemoprophylaxis is warranted in
patients receiving immunosuppressive therapy and patients
with previous disorders such as pulmonary disease [20].
Furthermore, physicians should be aware of the possibility
of combined opportunistic infections.
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